Business
First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease
Herantis Pharma Plc – Press release First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease HER-096 is a first-in-class agent in development for the treatment of Parkinson’s disease with disease modifying potential and convenient subcutaneous administrationSuccessful completion of the first patient cohort in Part 2 of the trial and approval to proceed from the Data and Safety Monitoring BoardPrimary objective is to assess the safety, tolerability and ph
About this update from Herantis Pharma Plc
[{"type":"image","alt":"Herantis Pharma plc","displaySize":"","headline":null,"caption":"Herantis Pharma plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":51,"url":"https://media.zenfs.com/en/globenewswire.com/6e517fc0c42b7af0b4fe04e9fd7ab646"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TztkX3djp9fmQ02UkZu7vQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6e517fc0c42b7af0b4fe04e9fd7ab646","width":300,"height":51}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":545,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/a77be4ab3b886ea3cb2421baee757382"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pvBZHDFCe9ajtkYxDstL8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a77be4ab3b886ea3cb2421baee757382","width":545,"height":92}}},{"type":"text","content":"Herantis Pharma Plc – Press release","length":35,"tagName":"p"},{"type":"text","content":"First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease","length":98,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"HER-096 is a first-in-class agent in development for the treatment of Parkinson’s disease with disease modifying potential and convenient subcutaneous administration","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Successful completion of the first patient cohort in Part 2 of the trial and approval to proceed from the Data and Safety Monitoring Board","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"Primary objective is to assess the safety, tolerability and pharmacokinetics of repeated subcutaneous doses of HER-096; the trial will also evaluate selected biomarkers, discover and identify novel treatment response biomarkers and monitor symptoms associated with Parkinson’s disease","length":284,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline data from Phase 1b trial is expected in September 2025","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Trial funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK","length":96,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":745,"o...